MUC1, a new hypoxia inducible factor target gene, is an actor in clear renal cell carcinoma tumor progression
about
Membrane-bound mucins: the mechanistic basis for alterations in the growth and survival of cancer cellsLactobacillus rhamnosus GG culture supernatant ameliorates acute alcohol-induced intestinal permeability and liver injuryThe impact of hypoxia on intestinal epithelial cell functions: consequences for invasion by bacterial pathogensTargeting hypoxic response for cancer therapyPersonalized characterization of diseases using sample-specific networksRepression of PLA2R1 by c-MYC and HIF-2alpha promotes cancer growthYC-1 induces G0/G1 phase arrest and mitochondria-dependent apoptosis in cisplatin-resistant human oral cancer CAR cellsMUC1: a multifaceted oncoprotein with a key role in cancer progression.Impact of MUC1 mucin downregulation in the phenotypic characteristics of MKN45 gastric carcinoma cell lineExpression of MUC17 is regulated by HIF1α-mediated hypoxic responses and requires a methylation-free hypoxia responsible element in pancreatic cancerReduced mRNA expression level of corticotropin-releasing hormone-binding protein is associated with aggressive human kidney cancer.O-glycan profiling of serum glycan for potential renal cancer biomarkers.Hypoxia Up-Regulates Galectin-3 in Mammary Tumor Progression and Metastasis.Muc1 is protective during kidney ischemia-reperfusion injuryTrial Watch: Therapeutic vaccines in metastatic renal cell carcinomaMUC1 mucin stabilizes and activates hypoxia-inducible factor 1 alpha to regulate metabolism in pancreatic cancer.Adrenomedullin 2 (ADM2) Regulates Mucin 1 at the Maternal-Fetal Interface in Human Pregnancy.Hypoxia-regulated target genes implicated in tumor metastasis.Design and characterization of the tumor vaccine MGN1601, allogeneic fourfold gene-modified vaccine cells combined with a TLR-9 agonist.Update on vaccine development for renal cell cancer.Polypeptide N-acetylgalactosaminyl transferase 3 independently predicts high-grade tumours and poor prognosis in patients with renal cell carcinomas.N-acetylgalactosaminyltransferases in cancer.Diagnostic and prognostic role of preoperative circulating CA 15-3, CA 125, and beta-2 microglobulin in renal cell carcinoma.MUC1 and metastatic cancer: expression, function and therapeutic targeting.Eukaryotic protein glycosylation: a primer for histochemists and cell biologistsHigh expression of Mucin13 associates with grimmer postoperative prognosis of patients with non-metastatic clear-cell renal cell carcinoma.MUC1-C nuclear localization drives invasiveness of renal cancer cells through a sheddase/gamma secretase dependent pathway.The role of cancer-associated myofibroblasts in intrahepatic cholangiocarcinoma.A novel personalized vaccine approach in combination with targeted therapy in advanced renal cell carcinoma.MUC1: a novel metabolic master regulator.Targeting miR-21 decreases expression of multi-drug resistant genes and promotes chemosensitivity of renal carcinoma.Epithelial to Mesenchymal Transition in Renal Cell Carcinoma: Implications for Cancer Therapy.Establishment of a human 3D lung cancer model based on a biological tissue matrix combined with a Boolean in silico model.Caveolin-1 in renal cell carcinoma promotes tumour cell invasion, and in co-operation with pERK predicts metastases in patients with clinically confined disease.MUC1 enhances hypoxia-driven angiogenesis through the regulation of multiple proangiogenic factors.Chemokine C-C motif receptor 5 and C-C motif ligand 5 promote cancer cell migration under hypoxia.Overexpression of MUC1 enhances proangiogenic activity of non-small-cell lung cancer cells through activation of Akt and extracellular signal-regulated kinase pathways.Insulin-like growth factor binding protein 7 and tissue inhibitor of metalloproteinases-2: differential expression and secretion in human kidney tubule cells.Hypoxia-induced oxidative stress promotes MUC4 degradation via autophagy to enhance pancreatic cancer cells survivalMitochondrial deficiency impairs hypoxic induction of HIF-1 transcriptional activity and retards tumor growth
P2860
Q24601584-82CBF4A3-A976-4DFF-8676-659E154985DFQ24629732-4ED90C3F-C6AD-479D-AFE8-D271EF518C5BQ26752794-5E705A44-9804-47C5-B0D1-8F6CABE2CB01Q26767351-F33CCD5A-4A19-4BB2-A810-A97FF9D67D9BQ28586781-34BEBD55-2CE6-4333-B76A-2E58B191DFDEQ33572229-1D86784E-6575-48CE-A7C0-80E9144A2A91Q33821469-FF93CC6B-9D36-4C5D-AB85-E33B3495166FQ33880143-7CC55574-988C-42F1-B524-7DAA8329DA79Q34071695-D09264A6-5D2D-41AE-87B4-6097C26BB8E8Q34412211-E5357C6A-C078-49E4-B26F-4BC5BC8BAFD0Q34680677-50D0941B-E60A-4D7A-A2EF-2002ADCA22E7Q34777759-B6E35946-0374-48D9-B4A5-60386B02B5CCQ35723085-940130D2-878F-4CAE-9ADB-D19B525FA56AQ35749664-B782752C-2347-4947-AFB3-0D634CAFA8C9Q35799377-C0D42EB2-13B1-43E9-A0BC-F10DCA8BE52DQ36187161-C8C0073E-E8EE-4FBC-A32C-7A5CE666DF72Q36461998-2CFD4CD1-2621-456F-A376-4E83A81C952DQ36521763-908CCE6D-2A52-4FC0-BE29-032F859F2F09Q36777133-CAEB38A6-6223-4658-9508-B56A14B8C6F0Q36989720-21745AB9-B493-453C-A017-CE92BC779F85Q37040588-E493A0FF-81FD-4BDA-B6DD-DF7883CF281FQ37619873-22309A40-6200-4CC6-A3D7-F08A9BFB9401Q37627345-B6CD8AD2-0310-4D5C-BE84-19F497507AEAQ37636939-23ECBD4B-A170-4398-9A33-E253E9CB344FQ37639440-35D69594-4611-4AFA-BBCF-AA939D098832Q37702565-9FB7E28F-FC9D-4980-A687-D274660E13BBQ37718458-6F0332F0-014D-44A5-9504-A427ABEFFEADQ37964960-9B0C2B59-7EA4-4B5E-9A79-AC0CA53940BCQ38172644-C66C2549-8C6C-481E-9895-5DDEA765CA26Q38177983-374A51CE-79B6-4F82-85A9-3DA2E0CAAF59Q38697133-EB93880D-8719-4845-969C-FADA438BAADCQ38759490-298E3775-D009-470E-9319-8C09C49F46B4Q39037578-7D860710-F370-4D1D-A11C-56A5FABEAFB1Q39080461-11D0BA74-2AD3-43B5-809E-1E588B6FF22DQ39251872-D4012373-0DAB-4A97-A55B-AEDDA27DDDA3Q39387590-0943EC8D-D9AD-4D46-A00C-9E1DD175A46FQ39465548-81854B2A-036A-4C87-933B-8A1AD421D809Q40413253-3539F43D-611B-45CD-8455-ECB77422B606Q41576862-B957F30C-E7CC-43CC-A676-09FC6E86D78AQ42244179-F1BAD1DD-AAC0-4E41-8B77-C10E9313C577
P2860
MUC1, a new hypoxia inducible factor target gene, is an actor in clear renal cell carcinoma tumor progression
description
2009 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
artículu científicu espublizáu en 2009
@ast
im Juli 2009 veröffentlichter wissenschaftlicher Artikel
@de
scientific journal article
@en
vedecký článok (publikovaný 2009/07/15)
@sk
vědecký článek publikovaný v roce 2009
@cs
wetenschappelijk artikel (gepubliceerd op 2009/07/15)
@nl
наукова стаття, опублікована в липні 2009
@uk
مقالة علمية (نشرت في 15-7-2009)
@ar
name
MUC1, a new hypoxia inducible ...... ll carcinoma tumor progression
@ast
MUC1, a new hypoxia inducible ...... ll carcinoma tumor progression
@en
MUC1, a new hypoxia inducible ...... ll carcinoma tumor progression
@nl
type
label
MUC1, a new hypoxia inducible ...... ll carcinoma tumor progression
@ast
MUC1, a new hypoxia inducible ...... ll carcinoma tumor progression
@en
MUC1, a new hypoxia inducible ...... ll carcinoma tumor progression
@nl
prefLabel
MUC1, a new hypoxia inducible ...... ll carcinoma tumor progression
@ast
MUC1, a new hypoxia inducible ...... ll carcinoma tumor progression
@en
MUC1, a new hypoxia inducible ...... ll carcinoma tumor progression
@nl
P2093
P3181
P1433
P1476
MUC1, a new hypoxia inducible ...... ll carcinoma tumor progression
@en
P2093
Brigitte Hémon
Michaël Perrais
Nicolas Briez
Réjane Lepoivre
Sébastien Aubert
Valérie Fauquette
Xavier Leroy
P304
P3181
P356
10.1158/0008-5472.CAN-08-4905
P407
P577
2009-06-23T00:00:00Z